Aurigene Oncology Ltd. has divulged compounds acting as dual antagonists of adenosine receptor A2A (ADORA2A) and programmed cell death 1 ligand 1 (CD274; PD-L1) reported to be useful for the treatment of cancer.
Oregon Health and Science University (OHSU) and the Southern Research Institute have patented compounds reported to be useful for the treatment of alphaviral infections.
Nodus Oncology Ltd. presented the discovery of NODX-010, a potent poly(ADP-ribose) glycohydrolase (PARG) inhibitor being developed for the potential treatment of cancer, including tumors resistant to PARP inhibitors.
The University of Wisconsin-Madison has synthesized a next-generation prostate-specific member antigen (PSMA)-targeting small molecule, ART-101, for the treatment of advanced prostate cancer.
Retinitis pigmentosa (RP) is the most common hereditary degenerative eye disease that leads to progressive vision loss, primarily caused by retinal degeneration.
Although antifibrotic agents can contribute to suppressing renal function decline when administered in combination with existing treatments for chronic kidney disease, drugs targeting kidney fibrosis have yet to reach the clinic.
RSS
